Nycomed Canada Solidifies Leadership Position in the Canadian Respiratory Market

OAKVILLE, ON, June 26 /CNW/ - Nycomed Canada Inc. today announced a licensing agreement with Chiesi Farmaceutici SpA to market Atimos(R) (formoterol), a treatment anticipated to be indicated for asthma and Chronic Obstructive Pulmonary Disease (COPD). In Canada, COPD is the fourth-leading cause of death among Canadians, and recently The Lung Association reported that COPD may affect nearly three million diagnosed and undiagnosed Canadians.